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Pyrroline-5-carboxylate reductase (PYCR) is the final enzyme
in proline biosynthesis, catalyzing the NAD(P)H-dependent
reduction of 1-pyrroline-5-carboxylate (P5C) to proline. Mu-
tations in the PYCR1 gene alter mitochondrial function and
cause the connective tissue disorder cutis laxa. Furthermore,
PYCR1 is overexpressed in multiple cancers, and the PYCR1
knock-out suppresses tumorigenic growth, suggesting that
PYCR1 is a potential cancer target. However, inhibitor develop-
ment has been stymied by limited mechanistic details for the
enzyme, particularly in light of a previous crystallographic study
that placed the cofactor-binding site in the C-terminal domain
rather than the anticipated Rossmann fold of the N-terminal
domain. To fill this gap, we report crystallographic, sedimenta-
tion-velocity, and kinetics data for human PYCR1. Structures of
binary complexes of PYCR1 with NADPH or proline deter-
mined at 1.9 Å resolution provide insight into cofactor and sub-
strate recognition.We seeNADPHbound to theRossmann fold,
over 25 Å from the previously proposed site. The 1.85 Å resolu-
tion structure of a ternary complex containing NADPH and a
P5C/proline analog provides a model of the Michaelis complex
formed during hydride transfer. Sedimentation velocity shows
that PYCR1 forms a concentration-dependent decamer in solu-
tion, consistent with the pentamer-of-dimers assembly seen
crystallographically. Kinetic andmutational analysis confirmed
several features seen in the crystal structure, including the
importance of a hydrogen bond between Thr-238 and the sub-
strate as well as limited cofactor discrimination.
Proline, a unique amino acid that lacks a primary amino
group, is a key building block of proteins and plays an important
role in stress protection and redox balance of cells across mul-
tiple kingdoms (1–3). The biosynthesis of proline occurs via
two pathways to produce the intermediate 1-pyrroline-5-car-
boxylate (P5C)2 from glutamate or ornithine (Fig. 1). The
glutamate route involves two enzymatic steps catalyzed se-
quentially by glutamate-5-kinase and -glutamate phosphate
reductase, producing L-glutamate -semialdehyde, which forms a
nonenzymatic equilibrium with P5C. In later evolved eu-
karyotes, this transformation is catalyzed by P5C synthetase, a
bifunctional enzyme that possesses both glutamate-5-kinase
and -glutamate phosphate reductase activities. The route
from ornithine is catalyzed by ornithine--aminotransferase,
which likewise produces L-glutamate -semialdehyde. The glu-
tamate and ornithine pathways converge on P5C reductase
(P5CR, EC 1.5.1.2), which catalyzes the final reduction of P5C
to proline using NAD(P)H.
In humans, P5CR is known as PYCR. The human genome
contains three homologous PYCR genes, PYCR1, PYCR2, and
PYCRL (also known as PYCR3), which produce a total of nine
PYCR enzyme isoforms. Supplemental Table S1 lists the pair-
wise sequence identities between the isoforms. Supplemental
Fig. S1 shows a global sequence alignment of PYCR enzymes.
The various PYCR isoforms have specialized roles in proline
biosynthesis and different subcellular localizations. A study of
PYCRs inmelanoma cells showed that both PYCR1 and PYCR2
function primarily in the glutamate-to-proline pathway,
whereas PYCRL functions mainly in the ornithine route to
proline (4). PYCR1 and -2 localize to mitochondria, where-
as PYCRL is cytosolic (4, 5). Other studies have shown that
PYCR1/2 is recoverable from the cytosol, suggesting the possi-
bility that the enzymes associate with the outer mitochondrial
membrane (6).
PYCR has been implicated in various cancers and has
emerged as a potential therapeutic target. A study of mRNA
profiles from 1,981 tumors identified PYCR1 as one of themost
consistently overexpressed metabolic genes across 19 different
cancer types (7). Additional studies highlight an abundance of
PYCR1 in melanoma cells as compared with healthy melano-
cytes, indicating this enzyme as a potential therapeutic target in
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skin cancer treatment (8, 9). Similarly, depletion of PYCR1 in
different types of cancers, such as breast, prostate, and renal cell
carcinoma, is associated with diminished cell proliferation and
tumorigenic growth (8, 10–12).
Deficiencies in PYCR are also linked to inherited metabolic
disorders. Certainmutations in thePYCR1 gene cause the auto-
somal recessive connective tissue disorder cutis laxa (5). The
decrease in PYCR1 activity is thought to impair mitochondrial
function, leading to developmental defects through increased
apoptosis (5). Mutations in the PYCR2 gene cause a develop-
mental disorder of the brain characterized by microcephaly,
hypomyelination, and reduced white matter (13). As with cutis
laxa, the pathogenicity of the disorder involves mitochondria-
induced apoptosis in the central nervous system (13).
Although crystal structures of P5CRs from microorganisms
and a plant species have been described (14–16), only one
structural study has been reported on human P5CR. Ten years
ago,Meng et al. (17) reported 3.1 Å crystal structures of PYCR1
complexed with NADPH and NADH. A major conclusion of
that study was that the NAD(P)H cofactor binds to the C-ter-
minal domain rather than in the canonical sitewithin theN-ter-
minal Rossmann fold domain (17). This result is notable
because it contradicts other P5CR structures and departs from
the accepted structure-function paradigm of Rossmann fold
enzymes, which asserts that the cofactor binds to the N termini
of the strands of the Rossmann dinucleotide-binding fold.
Herein we reexamine the structure of PYCR1 at high resolu-
tion to better establish the location of the active site and eluci-
date the interactions responsible for cofactor and substrate rec-
ognition. Crystal structures of binary complexes of PYCR1with
NADPH and proline have been determined at 1.9 Å resolution.
The structure of a ternary complex with NADPH and the
P5C/proline analog L-tetrahydrofuroic acid (THFA) has been
obtained at 1.85 Å resolution. Furthermore, we present analyt-
ical ultracentrifugation analysis of PYCR1 in solution and
kinetic data for the forward reaction of P5C reduction to pro-
line. In contrast to the previous study (17), our electron density
maps unequivocally identify the location of the cofactor-bind-
ing site and show that PYCR1 follows the canonical structure-
function paradigm of Rossmann fold enzymes.
Results
Tertiary and quaternary structure of PYCR1
High-resolution crystal structures of PYCR1 were deter-
mined in space groups P21212 and C2 (Table 1). The protomer
consists of an N-terminal / domain and a C-terminal 
domain (Fig. 2A). The N-terminal domain features the classic
Rossmann dinucleotide-binding fold, which consists of a pair of
motifs that interact across a pseudo-2-fold axis to form
a six-stranded parallel -sheet with strand order 321456 (18,
19). An additional  substructure follows strand 6 such that
the full -sheet of the N-terminal domain has eight -strands,
with the last two strands antiparallel to the Rossmann strands.
-Strand 8 of the N-terminal domain connects to the C-termi-
nal domain, which consists of a bundle of six -helices. The
C-terminal domain plays a major role in oligomerization. For
example, the C-terminal domain mediates dimerization (Fig.
2B). In the dimer, the C-terminal domains of two protomers
form an interlocking bundle of helices. Overall, the domain
architecture of PYCR1 is typical for P5CRs (14).
The oligomeric state of PYCR1 in solution was determined
with analytical ultracentrifugation using sedimentation veloc-
ity. Initial studies performed at 0.8 mg/ml (24 M) revealed a
distribution of apparent sedimentation coefficient that exhibits
a series of peaks in the range 1–7.5 S (Fig. 3A). The correspond-
ing distribution of molecular masses reveals multiple species in
solution spanning from 30 to 350 kDa (Fig. 3B). Because the
theoretical molecular mass of a monomer is 34 kDa, the c(M)
distribution is consistent with the presence of multiple oligo-
meric states ranging from monomer to decamer. To further
investigate the possibility that decamer formation is concen-
tration-dependent, sedimentation velocity was also performed at
the higher concentration of 6 mg/ml (180 M). This experiment
yielded a sedimentation coefficient distribution with a single peak
at 7.47 S (Fig. 3A), corresponding to a molecular mass of 350 kDa
(Fig. 3B). Thus, at a concentration of 180 M, PYCR1 is almost
entirely decameric. These results are consistent with P5CR form-
ing a self-association equilibrium in solution.
Analysis of crystal packing with PDBePISA (20) reveals a
pentamer-of-dimersassembly inbothcrystal forms(Fig.4), con-
Figure 1. The reactions and enzymes of proline biosynthesis. G5K, glutamate-5-kinase; -GPR, -glutamate-phosphate reductase; OAT, ornithine-
-aminotransferase.
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sistent with the decamer observed in sedimentation-velocity
experiments. This assembly is also present in other P5CR crys-
tal structures from a variety of organisms (14–16). The consis-
tency of this assembly across space groups and kingdoms suggests
the decamer is a fundamental structural property of P5CRs.
The P5CRdecamer has been described in detail elsewhere, so
only a summary is provided here (14, 15, 17). The decamer is a
pentamer-of-dimers assembly that resembles an “hourglass-
shaped barrel” (14) when viewed perpendicular to the 5-fold
axis (Fig. 4). The dimers are arranged such that the N-terminal
domains form pentameric rings at the top and bottom of the
barrel, and the C-terminal domains form a cylinder that con-
nects the two rings. A notable feature of the decamer is that
most of the interfacial surface area results from the interaction
betweenC-terminal domains, whereas theN-terminal domains
are relatively isolated from other protomers (Fig. 4B).
Identification of the NAD(P)H-binding site
Electron density maps clearly revealed the location and con-
formation of NADPH bound to PYCR1 (Fig. 5). In the binary
enzyme-NADPH complex structure, the density is very strong
in two of the five chains in the asymmetric unit, allowing mod-
eling of the complete cofactor with occupancy of 1.0 (chains C
and E). The cofactor was not modeled in the other three chains
(A, B, andD).We note that high occupancy of NADPH appears
to be correlated with stabilization of residues 34–40, which
form a loop that interacts with the adenosine portion of
NADPH. Density for this loop is very strong in chains C and E
butmuchweaker in chainsA, B, andD.The loopwas omitted in
chain A.
NADPH binds at the C termini of the strands of the Ross-
manndinucleotide-binding fold (Fig. 5). The cofactor adopts an
extended conformation with the pyrophosphate poised above
theN terminus of the first helix of the Rossmann fold (A). The
adenosine group interacts with the first motif, whereas
the nicotinamide riboside contacts the secondmotif. In
summary, NADPH adopts the canonical pose expected for
nicotinamide adenine dinucleotides bound to Rossmann fold
domains (21).
NADPH forms several noncovalent interactions with the
enzyme (Fig. 5). The ribose hydroxyls and pyrophosphate
hydrogen bond exclusively with protein backbone atoms. Only
Table 1
Data collection and refinement statistics
The values for the outer resolution shell of data are given in parenthesis.
Parameter NADPH Pro NADPH/THFA Ligand-free P21212 Ligand-free C2
Space group P21212 P21212 P21212 P21212 C2
Unit cell parameters
a (Å) 162.1 165.1 161.5 163.03 183.8
b (Å) 87.8 87.7 87.7 88.1 120.7
c (Å) 115.9 117.3 115.6 117.3 88.1
 (degrees) 109.2
Wavelength 1.000 1.000 1.000 1.000 1.000
Resolution (Å) 64.24–1.92 (1.95–1.92) 64.63–1.90 (1.93–1.90) 64.10–1.85 (1.88–1.85) 64.68–1.85 (1.88–1.85) 60.34–1.85 (1.88–1.85)
Observations 879,308 (35,441) 993,789 (45,238) 978,352 (38,421) 1,301,444 (45,882) 678,751 (21,389)
Unique reflections 126,545 (6,217) 133,932 (6,541) 139,847 (6,540) 144,477 (7,100) 153,414 (7,335)
Rmerge(I) 0.094 (0.965) 0.105 (0.899) 0.080 (0.858) 0.075 (0.902) 0.055 (0.672)
Rmeas(I) 0.101 (1.065) 0.113 (0.971) 0.087 (0.941) 0.079 (0.981) 0.062 (0.821)
Rpim(I) 0.038 (0.443) 0.040 (0.366) 0.033 (0.380) 0.024 (0.384) 0.027 (0.462)
Mean I/ 14.9 (1.7) 10.6 (1.5) 19.3 (1.9) 18.7 (2.0) 16.1 (1.4)
Mean CC1⁄2 0.999 (0.720) 0.997 (0.846) 0.999 (0.699) 0.999 (0.789) 0.999 (0.688)
Completeness (%) 100.0 (99.9) 99.7 (99.9) 99.7 (95.0) 100.0 (99.0) 99.3 (95.9)
Multiplicity 6.9 (5.7) 7.4 (6.9) 7.0 (5.9) 9.0 (6.5) 4.4 (2.9)
No. of atoms 10,557 10,250 11,035 10,567 10,002
Protein 9,877 9,712 10,089 9,974 9,495
NADPH 96 NAa 240 NA NA
Pro or THFA NA 40 40 NA NA
Water 557 438 659 568 502
Rcryst 0.174 (0.248) 0.196 (0.315) 0.172 (0.244) 0.180 (0.266) 0.172 (0.269)
Rfreeb 0.211 (0.274) 0.228 (0.362) 0.200 (0.261) 0.2157 (0.295) 0.200 (0.279)
RMSDc bond
lengths (Å)
0.011 0.005 0.007 0.012 0.014
RMSD bond
angles (degrees)
1.099 0.699 0.907 1.157 1.273
Ramachandran plotd
Favored (%) 97.57 98.08 97.97 97.94 97.75
Outliers (%) 0.00 0.00 0.00 0.00 0.00
Clashscore (PR)d 1.86 (100) 1.60 (100) 1.35 (100) 3.39 (98) 2.13 (99)
MolProbity score (PR)d 1.10 (100) 1.03 (100) 0.92 (100) 1.54 (93) 1.36 (98)
Average B-factor (Å2)
Protein 32.2 43.3 26.2 38.8 35.5
NADPH 32.5 NA 25.8 NA NA
Pro or THFA NA 40.2 26.6 NA NA
Water 33.2 38.4 30.3 34.5 36.3
Coordinate error (Å)e 0.19 0.23 0.18 0.20 0.20
PDB entry 5UAT 5UAU 5UAV 5UAW 5UAX
a NA, not applicable.
b 5% test set.
c RMSD, root mean square deviation.
d FromMolProbity. The percentile ranks (PR) for Clashscore and MolProbity score are given in parenthesis.
e Maximum likelihood-based coordinate error estimate reported by phenix.refine.
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two side chains participate in hydrogen bonding with NADPH.
Asn-56 hydrogen-bonds with the adenine ring, whereas Ser-34
interacts with the 2-phosphoryl. Note that Asn-56 is present in
all PYCR isoforms (supplemental Fig. S1). Ser-34 is present in
all of the isoforms except PYCR3,which hasAla in this position.
Nonpolar side chains help position the bases of NADPH, with
Pro-35, Val-70, and Ile-78 contacting the adenine and Leu-11
packing against the nicotinamide. Pro-35 is present all human
PYCR isoforms, whereas Val-70 and Ile-78 are replaced by Thr
and Val in PYCR3 (supplemental Fig. S1).
The carboxamide of NADPH has a 2-fold rotational degen-
eracy at the resolution of our structures; however, hydrogen
bonding can be used to deduce the correct orientation of this
group. The carboxamide amino group has been modeled so it
forms an intramolecular hydrogen bond with the pyrophos-
phate and another hydrogen bond with the backbone carbonyl
of Asn-230 (Fig. 5). In contrast, rotation by 180° places the car-
boxamide carbonyl next to obligate hydrogen bond acceptors,
resulting in no hydrogen bonds.
The proline-binding site
The structure of PYCR1 complexed with the product L-pro-
line was determined at 1.90 Å resolution from a crystal that had
been soaked in 1.8 M proline (Table 1 and Fig. 6). The electron
density allowed modeling of proline in the active site of all five
chains with occupancy of 1.0. We note that a sulfate ion occu-
pies the proline site in the ligand-free orthorhombic structure.
Prolinewas alsomodeled into an election density feature on the
surface of the protein near Thr-137. The adventitious binding
of proline to the protein surface is common when used in high
concentration as a cryoprotectant, as is the case here (22).
Proline binds in a section of the dimer interface where the
K-L loop of one protomermeets -helices H, I, andM of the
other protomer (Figs. 2B and 6A). The carboxylate and amino
groups of proline are anchored to the K-L loop via several
hydrogen bonds, some of which are mediated by a water mole-
cule (Fig. 6A). Of note is the hydrogen bond between Thr-238
and the amino group of proline. It has been proposed that this
conserved residue functions in catalysis by donating a proton to
the imine nitrogen atom of P5C (14).
The roof of the binding site provides nonpolar contacts for
themethylene groups of proline. These contacts includeAla-97
of the Rossmann fold and the kink between helices H and I
(Fig. 6B). The kink is caused by the presence of conserved Pro-
Figure 2. Structures of the PYCR1 protomer and dimer. A, structure of the
protomer of the ternary complex with NADPH and the proline/P5C analog
THFA. The N-terminal NAD(P)H-binding domain is colored according to sec-
ondary structure, with -strands in pink and -helices in blue. The C-terminal
oligomerization domain is colored gray. NADPH appears in gold sticks. THFA is
shown as cyan sticks. -Strands are labeled 1–8; -helices are labeled A–M.
Helix-disrupting Pro-178 is shown. B, structure of the dimer. The -helices of
the C-terminal domain are labeled H–M for the gray protomer and H–M
for the purple protomer. NADPH and THFA are colored gold and cyan, respec-
tively. The arrow represents the 2-fold axis of the dimer.
Figure3.OligomerizationofPYCR1 in solution.A, apparent sedimentation
coefficient distribution determined at 6 mg/ml (solid line) and 0.8 mg/ml
(dashed line).B,molecularmassdistributiondeterminedat 6mg/ml (solid line)
and 0.8 mg/ml (dashed line).
Structures of PYCR1
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178 and appears to be a common feature of P5CRs, because it is
also present in structures of P5CR from microorganisms (14).
Within the kink, the carbonyls of residues 174 and 175 splay
outward to avoid steric clash with the C of Pro-178, and as a
result, these groups do not form i to i 4 hydrogen bonds, and
the helical structure is disrupted. Thr-171 and Gly-175 of the
kink region provide nonpolar contacts with the methylene
groups of proline. These interactions bury the carboxylate face
of the proline, leaving the other face solvent-exposed and avail-
able for catalysis (Fig. 6B).
The ternary complex with NADPH and THFA
The structure of PYCR1 complexedwithNADPHandTHFA
was determined at 1.85 Å resolution (Table 1 and Fig. 7). The
electron density is very strong for both ligands in all five chains,
allowing inclusion of the ligands in the model at an occupancy
of 1.0. This is the first structure of any P5CR that mimics the
enzyme-NADPH-P5C Michaelis complex.
The structure shows that dimerization is essential for cata-
lytic activity. NADPH interacts with the Rossmann fold of one
protomer, and THFA binds in the K-L loop of the opposite
protomer of the dimer (Fig. 2B). NADPH adopts the same con-
formation as in the binary enzyme-NADPH complex, whereas
THFA occupies the proline site described under “The proline-
binding site.” Water-mediated hydrogen bonding appears to
play a role in stabilizing the ternary complex, because five wa-
ter molecules with strong electron density connect THFA,
NADPH, and the protein (Fig. 7). The ring of THFA stacks in
parallel with the nicotinamide such that theC5 of THFA,which
represents the hydride acceptor atom of P5C, is 3.7 Å from the
C4 of the nicotinamide. The structure is consistentwith a direct
hydride-transfer mechanism.
Comparisonwith previous human PYCR1 structures
As noted in the Introduction, the first report of the human
PYCR1 structure appeared in 2006 fromMeng et al. (17). This
paper described structures of the ligand-free enzyme (PDB
code 2GER), a ternary complex with NADH and the “substrate
analog” glutamate (PDB code 2GR9), and another ternary com-
plexwithNADPHand glutamate (PDB code 2GRA). The struc-
tures were solved at 3.1 Å resolution and contained the
Figure 4. The PYCR1 pentamer-of-dimers decamer. A, two orthogonal
views of the decamer, with each chain differently colored. B, two orthogonal
viewsof thedecamer,with theN-terminal domains colored blue and theC-ter-
minal domains colored gray. Note that the C-terminal domains mediate all
protein-protein interactions in the decamer.
Figure 5. Electron density and interactions for NADPH bound to PYCR1.
The cage represents a simulated annealing Fo  Fc map contoured at 3.
Selected -helices and -strands are labeled in accordance with Fig. 2A. Helix
K (purple) is from the opposite protomer of the dimer. The conserved water
molecule of the Rossmann dinucleotide-binding fold is colored green (21).
Figure 6. The proline-binding site. A, electron density and interactions for
proline (cyan) bound to PYCR1. The cage represents a simulated annealing
Fo  Fc map contoured at 3. The two protomers of the dimer are colored
purpleandgray.Note thatprolinebinds in thedimer interface.Selected-heli-
ces are labeled in accordancewith Fig. 2A. B, space-filling representation of the
proline-binding site highlighting nonpolar residues that contact the methyl-
ene groups of proline.
Structures of PYCR1
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expected fold as well as the same quaternary arrangement as
had been reported a year earlier for prokaryotic P5CR struc-
tures (14). However, Meng et al. (17) reported an unexpected
binding site for NAD(P)H located in the dimer interface (sup-
plemental Fig. S2A). Although the paper refers to the impor-
tance of the Rossmann fold in this structure, their dinucleotide-
binding site is over 25 Å away from the canonical NADPH site
in our structures. Notably, the NADPH site that we report here
is the same as that found in the structures of prokaryotic P5CRs
(14). Furthermore, the results ofMeng et al. (17) contradict the
many structures of other Rossmann fold proteins that have
been reported since the discovery of the fold in lactate dehydro-
genase in the 1970s (18, 19).
Because the interpretation ofMeng et al. (17) contradicts our
findings and differs from the conventional dinucleotide-bind-
ing model found in other NAD(P) enzymes with a Rossmann
fold, it is important to carefully study their binding site. Nota-
bly, Meng et al. (17) summarized the basis for modeling the
dinucleotide and glutamate as follows: “the entire cofactor and
substrate analog molecules could be placed accurately from
unambiguous electron density.” If the location of this unusual
dinucleotide-binding site is accurate, this result would add dra-
matically to our knowledge of the structural biology of P5CR
and Rossmann fold enzymes in general. On the other hand, if it
is in error, it is important that the record be adjusted.
Below, several aspects of the Meng et al. (17) structures are
reviewed, including the original electron density, the geometry
and close contacts of the modeled dinucleotide, the re-refined
structures that we obtained from the PDB_REDO server (23),
and finally simulated annealing omit maps calculated with the
dinucleotide and glutamate ligands excluded to remove phase
bias. In all of this analysis, the same answer has been obtained,
namely that the dinucleotide and glutamate ligands in the
Meng et al. (17) crystal form were built in error and should be
removed from the structure.
The human PYCR1 structures described by Meng et al. (17)
have space groupC2with five protomers in the asymmetric unit
(different from our C2 lattice; Table 1). A crystallographic
2-fold axis correctly generates the decamer. The fold is consis-
tent with previously reported P5CR structures as well as our
structures. Superposition of monomers from our structures
with those of Meng et al. (17) results in pairwise root mean
square differences of 0.7–1.0 Å, which indicates similar overall
folds. This similarity is evident from a superposition of dimers
from 2GR9 and our ternary complex (supplemental Fig. S2A).
Also, the Rossmann domains of the Meng et al. (17) structures
superimpose with our structures with root mean square differ-
ence of 0.5–0.9 Å (supplemental Fig. S2B). This low value sug-
gests that the canonical dinucleotide-binding site is available in
the Meng et al. (17) structures.
All of the cofactor-binding sites in 2GR9 and 2GRA were
reviewed for their steric contacts, molecular geometry, and
B-factors and the quality of the electron density. Serious con-
cerns have been identified. For example, although the 2Fo Fc
maps for 2GRA/9 obtained from the Electron Density Server
(24) have some coverage of the dinucleotide at 1 in some of the
chains (supplemental Figs. S3A and S4A), all five NAD(P)H-
binding locations contain strong negative Fo Fc density cov-
ering the ligand at negative 3 (supplemental Figs. S3B and
S4B). The average B-factors of NAD(P)H are also high: 76–94
Å2 in 2GRA and 84–195 Å2 in 2GR9 (supplemental Table S2).
For comparison, the average B-factors of NADPH in our ter-
nary complex are 19–33 Å2 (supplemental Table S2).
The structures also include a glutamate ligand modeled near
the nicotinamide. The authors suggest that this ligand is a “sub-
strate analog,” which presumably refers to the similarity
between Glu and L-glutamate -semialdehyde (Fig. 1). The
average B-factors of the Glu ligand are very high: 124–200 Å2
(supplemental Table S2). For comparison, the average B-fac-
tors of THFA in our ternary complex are 23–30Å2 (supplemen-
tal Table S2). Furthermore, there is a noticeable lack of 2Fo Fc
density at 1 for Glu in 9 of the 10 chains of the two structures
(supplemental Fig. S5). Although some electron density covers
part of the ligand in chainAof 2GRA, it is hard to argue that this
feature resembles Glu (supplemental Fig. S5).
Inspection of the cofactor geometry and dinucleotide envi-
ronment raises additional concerns. For example, Arg-129
makes close contacts of 1.7 and 1.4 Å with NADH in chains B
and C, respectively (supplemental Fig. S3). These distances
imply covalent bonding, which is impossible. Indeed, the
default settings of the graphics program PyMOL (25) interpret
these close contacts as covalent bonds and draw connections
between the atoms (supplemental Fig. S3). Similar abnormali-
ties are evident in theNADPHmodeled in 2GRA.One example
is found in chain D, where the carbonyl oxygen of Ser-154 is 1.8
Figure 7. Structure of the ternary complex of PYCR1 with NADPH and THFA. The cage represents a simulated annealing Fo Fc map contoured at 3.
NADPH and THFA are colored gold and cyan, respectively. The two protomers of the dimer are colored purple and gray. Two orthogonal views are shown.
Selected -helices are labeled in accordance with Fig. 2A.
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Å from the nicotinamide amino group, close enough for
PyMOL to draw a covalent bond (supplemental Fig. S4).
The NADH in chain E of 2GR9 provides one example of
severe steric clash and poor geometry. The NADHmakes close
contacts of 0.6 and 1.5 Å with the modeled Glu ligand (supple-
mental Fig. S6). The pyrophosphate ofNADHdeviates substan-
tially from the expected tetrahedral geometry, displaying an
O–P–O bond angle of 83° and a P–O–C5 angle of 92° (supple-
mental Fig. S6). The distorted pyrophosphate makes a close
contact of 2.1 Åwith the adenosine ribose. Finally, the vector of
the N-glycosidic bond to adenine is not in the plane of the
nucleobase, which is unexpected (supplemental Fig. S6). All of
these findings (lack of electron density, impossibly close con-
tacts, and bad geometry) are consistent with inaccurate model-
ing and poor refinement of ligands into electron density maps.
The results reported here from studying the ElectronDensity
Server maps contrast with the density described by Meng et al.
(17). They report full coverage of both NADH and NADPH in
Fo Fc omit maps calculated at 1.7, but details of these calcu-
lations were not provided. To help clarify the nature of the
dinucleotide ligand density, we utilized the PDB_REDO server
(23) to review the density at these key sites in 2GR9 and 2GRA.
PDB_REDO maps generated using the conservative protocol
(besttls coordinate file) improved the geometry for the bound
cofactors, and the maps exhibited less negative Fo Fc density
surrounding the ligands. However, this apparent improvement
was accompanied by a substantial increase of the B-factors of
the bound ligands to values physically inconsistent with signif-
icant binding. For example, the average B-factors for NADH
and NADPH in the PDB_REDO structures are 198–271 Å2
(supplemental Table S2). The average B-factors for the gluta-
mate ligand increased to 169–229 Å2 (supplemental Table S2).
Consistent with the very high B-factors, the PDB_REDO struc-
tures have a conspicuous lack of 2Fo Fc density for the mod-
eled ligands.
All of the observations described above point to the
NAD(P)H-binding site in Meng et al. (17) being in error. To
explore what the density may have resembled before including
the ligands in the model, we used phenix.refine to calculate
simulated annealing omit maps. The Fo Fc omit maps lacked
density consistent with boundNAD(P)H at any of the five sites.
For example, Fo Fc density for NADH is essentially absent at
3 (supplemental Figs. S7A and S8A). There were patches of
positive Fo Fc density at 2 in some chains, but none resem-
bled a dinucleotide (supplemental Figs. S7B and S8B). As a pos-
itive control, we omitted the side chain of Phe-250 in addition
to the dinucleotide. In the omit map, Phe-250 is fully covered
with positiveFoFcdensity at 3 (supplemental Fig. S7C). This
finding is consistentwith the omitmaps being able to effectively
return density for an important feature that was left out of the
model. The lack of convincing positive Fo Fc omit density also
supports the conclusion that the modeling of the dinucleotide
and glutamate ligands in 2GR9 and 2GRA as reported byMeng
et al. (17) must be incorrect.
Kinetic measurements
Steady-state kinetics assays showed that PYCR1 utilizes both
NADH and NADPH cofactors (supplemental Fig. S9, A and B).
When keeping P5C fixed (3.5 mM) while varying the dinucle-
otide concentration,Km values of 70 and 283M forNADHand
NADPH were obtained (Table 2). The kcat value was nearly
3-fold higher with NADH, resulting in a 12-fold greater cata-
lytic efficiency (kcat/Km) relative to NADPH (Table 2). A previ-
ous study reported a 6.5-fold higher catalytic efficiency of
PYCR1withNADHoverNADPH (8). A kcat of 31 s1 andKm of
667 M L-P5C were determined for wild-type PYCR1 from
assays varying P5C while keeping NADPH constant (Table 2,
supplemental Fig. S9C).
The importance of Thr-238 was tested with the site-directed
mutation T238A. It has been proposed that this universally
conserved residue functions in catalysis by donating a proton to
the imine nitrogen of P5C (14). This proposition was based on
the observation of a hydrogen bond between the hydroxyl
group of the conserved Thr and the amino group of the product
proline in P5CR structures frommicroorganisms (14), an inter-
action that is also seen in human PYCR1 (Fig. 6A). The analo-
gous hydrogen bond to THFA is also present in the ternary
complex (Fig. 7).
Kinetic parameters for T238A were determined by varying
NADPH and P5C (supplemental Fig. S9, D and E). The esti-
mates of kcat were 23 and 14 s1 withKm values of 159 and 2887
M for NADPH and L-P5C, respectively (Table 2). Because the
estimated Km is near the upper concentration of P5C available,
a kcat/Km value of 16,700 M1 s1 was also estimated from the
slope of the linear region ([S] Km) of the Michaelis-Menten
plot. The 10-fold lower kcat/Km value of the T238A mutant
relative to wild-type PYCR1 with L-P5C is consistent with the
proposed role of Thr-238 hydrogen bonding to the substrate.
Discussion
Wedescribed the first high-resolution structures of a human
PYCR isozyme. Notably, the complex of PYCR1 with NADPH
Table 2
Steady-state kinetic parameters for PYCR1
Values reported are the best fit parameters from non-linear least squares fit to the Michaelis-Menten equation (supplemental Fig. S9).
Enzyme
Variable
substrate
Fixed
substrate Km kcat kcat/Km
M s1 M1 s1
Wild type NADH P5Ca 70 11 218 8 31 5.	 105
Wild type NADPH P5Ca 283 119 74 8 2.6 1.1	 105
Wild type P5C NADPHb 667 88c 31 2 0.47 0.07	 105
T238A NADPH P5Ca 159 47 23 2 1.4 0.4	 105
T238A P5C NADPHb 2,887 774c 14 3 0.05 0.02	 105
a Fixed DL-P5C concentration of 3.5 mM.
b Fixed NADPH concentration of 0.5 mM.
c Concentration of L-P5C, which is considered to be half the total DL-P5C concentration.
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and the P5C/Pro analogTHFA is the first structure of a relevant
ternary complex for any P5CR. This structure provides new
information about the mechanism of the enzyme. Considering
it to represent the E-NADPH-P5C Michaelis complex, the
structure implies that P5C binds with its ring approximately
parallel to the nicotinamide ring with C2 of P5C close to the C4
of NADPH, as expected for a hydride-transfer mechanism. The
donor-acceptor distance inferred from the structure is 3.7 Å,
whereas the expected distance in the transition state for
hydride-transfer reactions is 2.7 Å (26). It is possible that
fluctuations of the enzyme are needed to achieve the transition
state from the configuration represented in the crystal struc-
ture. Alternatively, our structure represents the product com-
plex (E-NADP-Pro) rather than the substrate complex.
The structure also immediately suggests the stereochemistry
of hydride transfer. Because the B-side of the nicotinamide con-
tacts the implied substrate, PYCR1 is predicted to catalyze the
transfer of the pro-4S hydrogen to P5C. This assignment agrees
with a previous prediction based on superimposing separate
structures of P5CR-NADP andP5CR-Pro complexes (14).We
are not aware of any reports of the determination of the stere-
ochemistry of P5CR by kinetic isotope effect measurements.
It has been suggested that a conservedThr or Ser in the active
site functions as a general acid that donates a proton to the
imine nitrogen of P5C (14). Ser and Thr are not usually consid-
ered to be general acid/base catalysts due to their high pKa
values. It is possible for the protein environment to lower the
pKa of an active site residue so it can function as a general acid,
as occurs for Lys-199 of the NAD-malic enzyme (27) and
Arg-69 of Sin resolvase (28). However, the active site of PYCR1
does not have a preponderance of positively charged residues
that could depress the pKa of the proposed residue.Wemutated
the residue in question of PYCR1 (Thr-238), which forms a
hydrogen bond to the proline amino group in our structure
(Fig. 6). Themutation to Ala did not substantially diminish kcat,
suggesting that Thr-238 is not essential for catalysis, whereas
kcat/Kmwith varied P5C was 10-fold lower relative to wild type,
indicating that the loss of Thr impacts P5C binding. For refer-
ence, we note that mutation of Lys-69 to Ala in the NAD-malic
enzyme decreases Vmax by 105 (27). Thus, it is concluded that
Thr-238 does not function as the general acid in PYCR1 but
appears to have important interactions with the imine group of
P5C, as corroborated by the structural and kinetic data.
As detailed under “Results,” the noncanonical dinucleotide-
binding site proposed by Meng et al. (17) is not supported by
the experimental data. The original cofactor ligand density was
poor, the difference density was uniformly and strongly nega-
tive, and the PDB_REDO pipeline essentially removed the con-
tribution of the cofactor andGlu ligands by elevating their tem-
perature factors to non-physical values (supplemental Table
S2). The cofactor also had poor geometry and formed several
bad contacts, all of which are inconsistent with a well-defined
ligand-binding site.
This is in sharp contrast to the highly conserved nature of
dinucleotide-binding sites in other Rossmann fold proteins.
First reported in the 1970s (18, 29), the Rossmann fold consists
of repeated / motifs and comprises six (typically) parallel
-strands with-helices packed on either side of the sheet (30).
The dinucleotide binds with an extended conformation in the
cleft found at the C termini of the strands, with the pyrophos-
phate interacting with the N terminus of A and the Gly-rich
1-A loop. Each base interacts with the opposing faces of the
sheet, forming a network of polar and non-polar interactions.
Our previous analysis of 102 Rossmann fold protein structures
representing 43 enzymes and 40 species demonstrated a
remarkably high consistency of the binding site structure and
cofactor conformation (21). In fact, the binding site is so con-
sistent that a conserved water molecule bridging the Gly-rich
loop and the pyrophosphate could effectively be considered
part of the dinucleotide-binding motif (21). Indeed, this water
molecule is present in our structures (Fig. 5). In this context,
it is surprising that a completely novel dinucleotide-binding
mode for PYCR1was proposedwith almost no discussion of the
important way in which the site deviated from conventional
wisdom.
Strong evidence from other structural studies also points to
themistaken nature of the unconventional binding site ofMeng
et al. (17). The core structural elements of human PYCR1 are
superimposable with those of available bacterial P5CR struc-
tures, and the dinucleotide ligands in the bacterial enzyme
structures conform to the classic paradigm for Rossmann fold
proteins (14). Furthermore, the PDB contains an unpublished
human PYCR1 structure (PDB code 2IZZ) that containsNAD
bound in the same location as our structure and bacterial P5CR
structures. All of the above structural work also supports the
conclusion that the binding site described byMeng et al. (17) is
incorrect.
Incorrect ligand-binding site notwithstanding, there are pos-
itive aspects to the work of Meng et al. (17). They were the first
to establish that the fold of PYCR1 is consistent with homo-
logous enzymes. In addition, they documented the oligomeric
state as a pentamer of intertwined dimers. These contributions
to the literature remain valid. Nevertheless, it is essential that
the record be corrected regarding the erroneous NAD(P)H-
binding site, andwe recommend that correction take place.We
also recommend that the recent in silico analysis of cutis laxa
PYCR1 mutants, which is based on the incorrect active site, be
reevaluated with the correct PYCR1 structure (32).
Our results might explain why the canonical dinucleotide-
binding site was unoccupied in the Meng et al. (17) structures.
To obtain complexes,Meng et al. (17) soaked crystals in 0.3mM
NADH or NADPH. Our measurements with PYCR1 indicate a
Km of 0.07 mM for NADH and 0.3 mM for NADPH (Table 2).
Thus, the dinucleotide concentrations used by Meng et al. (17)
may not have been high enough for saturation.
Many examples of incorrectly built structures or misplaced
ligands have appeared in the crystallographic literature over the
past few years (33–36). Some have arisen from updates in
genomic databases that revealed older structures solved with
incorrect sequences (33, 37, 38).Others are due to the very large
number of new structures appearing each year coupledwith the
fact that many of them come from laboratories with little
crystallographic experience (39). Further, there is pressure
now to produce faster, more numerous, and more novel
results in science (40), and ligand-binding density would be
an important source of novelty. Finally, reviewers are often
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judging structures without access to coordinate files and
electron density maps, making detailed verification of
ligands difficult. Taken together, this leads to a risk of inappro-
priate ligand placement.
It has been suggested that the risk of errors in ligand place-
ment could be mitigated by utilizing currently available struc-
tural tools (41, 42). These tools emphasize inspection of elec-
tron density, stereochemistry, and ligand environment (34, 41).
We suggest that the historical context of the ligand site also be
considered. In the case of a family like Rossmann dinucleotide-
binding proteins, which contain a highly conserved fold, very
strong proof should be required of the authors before propos-
ing a completely new binding site. Such safeguards would prob-
ably have prevented the misidentification of the active site of
PYCR1.
Experimental procedures
Expression and purification of PYCR1
DNA encoding humanmitochondrial PYCR1 transcript var-
iant 1 (NCBI RefSeq number NP_001269209.1) in pET-24b()
with codons optimized for expression in Escherichia coli was
synthesized byGenScript BiotechCorp. The construct encodes
residues 1–300 of the full-length 319-residue protein plus an
N-terminal hexahistidine tag and tobacco etch virus protease
cleavage site. This construct was designed for enhanced crys-
tallization based on unpublished PDB entry 2IZZ.
The PYCR1 construct was transformed into BL21(DE3)-
competent E. coli cells and plated onto LB agar containing 50
g/ml kanamycin. A starter culture of Luria broth medium,
shaken overnight at 37 °C and 250 rpm, was used to inoculate
two 1-liter cultures. After 2 h of shaking at 37 °C and 250 rpm,
the larger cultures were induced with 0.5 mM isopropyl -D-1-
thiogalactopyranoside and grown with continued shaking at
18 °C overnight. Centrifugation at 3,000	 g for 20 min at 4 °C
was used to collect the cells, whichwere then resuspended in 50
mM HEPES, pH 7.8, 300 mM NaCl, 10 mM imidazole, and 5%
(w/v) glycerol (buffer A). The resuspended pellet was stored at
80 °C until ready for purification.
A mixture of DNase I, lysozyme, and GoldBio ProBlock pro-
tease inhibitor mixture was added to thawed cells and stirred at
4 °C for 20 min. After lysing cells via sonication, cell debris was
removed by centrifugation at 16,000 rpm for 1 h at 4 °C. The
resulting supernatant was passed through a 0.45-m Mil-
lex-HV syringe filter and loaded onto a 5-ml HisTrap Ni2-
nitrilotriacetic acid column (GE Healthcare) pre-equilibrated
in buffer A using an AKTA Pure chromatography instrument.
The column was washed with buffer A supplemented with 30
mM imidazole and eluted with 300mM imidazole. The fractions
containing PYCR1 as determined by SDS-PAGEwere collected
and dialyzed at 4 °C overnight into 300 mM NaCl, 2% (w/v)
glycerol, and 50 mM HEPES at pH 7.5. Following dialysis, the
protein was concentrated to 5ml using a centrifugal concentra-
tor (Amicon Ultra-15) and then further purified on a HiLoad
16/600 Superdex 200 size-exclusion column (GE Healthcare)
using a column buffer with the same composition as the dialysis
buffer. The His tag was not removed.
Crystallization of PYCR1
Initial crystallization conditionswere identified usingHamp-
ton Research Index and Crystal Screen I and II reagents in sit-
ting drops (CrystalEX microplates) with 150-l reservoir vol-
umes. All screening trials were performed at 22 °C using drops
formed bymixing 1l of the protein stock solution with 1l of
reservoir solution. Cryschem M sitting drop plates were used
for optimizations, with 500-l reservoir volumes and drops
containing 1.5l of protein and 1.5l of the reservoir solution.
Microcrystals from initial hit conditions were used for streak
seeding to obtain diffraction-quality crystals.
Crystals in the space group P21212 were grown using reser-
voir solutions containing 300 mMNa2SO4, 16–18% (w/v) poly-
ethylene glycol (PEG) 3350, and 0.1 M HEPES at pH 7.5. The
unit cell dimensions area
 162Å, b
 88Å, and c
 116Å.The
asymmetric unit contains five PYCR1 molecules, which corre-
sponds to Vm of 2.43 Å3/Da and 49% solvent (43). The best
P21212 crystals diffracted to 1.85 Å resolution (Table 1).
A second crystal form in space group C2 was grown from
reservoir solutions containing 3 MNaCl and 0.1 MHEPES at pH
7.5–8.0. The unit cell dimensions are a
 184Å, b
 121Å, c

88 Å, and 
 109°. The asymmetric unit contains five PYCR1
molecules, which corresponds to Vm of 2.71 Å3/Da and 55%
solvent (43). TheC2 crystals also diffracted to 1.85 Å resolution
(Table 1). We note that this crystal form is different from the
PYCR1C2 forms ofMeng et al. (17) and unpublishedPDBentry
2IZZ.
Crystal soaking
The orthorhombic form was the better of the two crystal
forms for ligand soaking. Ligand-free P21212 crystals were pre-
pared for low temperature data collection by in situ serial trans-
fer into a solution containing the reservoir supplemented with
20% (v/v) PEG200, followed by rapid plunging into liquid nitro-
gen. The complex of PYCR1 with NADPH bound was obtained
by soaking ligand-free crystals in the 20% (v/v) PEG 200
cryobuffer supplemented with 100 mM NADPH. The complex
with proline bound was obtained by soaking a crystal in the
reservoir supplemented with 1.8 M proline. We note that this
level of proline provides cryoprotection (22). A ternary com-
plex with NADPH and the P5C/proline analog THFA was
formed by first soaking with the 20% PEG 200 cryobuffer sup-
plemented with 100 mM NADPH, followed by another short
soak in the cryobuffer supplemented with 50 mM THFA. The
ligand soaking times in all cases were10 min.
The C2 crystal form was less amenable to ligand soaking but
nevertheless afforded a high-resolution structure of the ligand-
free enzyme. The structure of the ligand-free enzyme in space
groupC2was solved from a crystal soaked in the reservoir solu-
tion supplemented with 30% (w/v) glycerol for cryoprotection
and 10mMNADP. Density forNADPwas not strong enough
to allow modeling of the ligand, so this structure is considered
to be “ligand-free.”
X-ray diffraction data collection, phasing, and refinement
X-ray diffraction data were collected on Advanced Light
Source beamline 4.2.2 at Lawrence Berkeley National Labora-
tory using a Taurus-1 detector in shutterless mode. Data were
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integrated and scaled with XDS (44). Intensities were merged
and converted to amplitudes with Aimless (45). Data pro-
cessing statistics are shown in Table 1.
Initial phases were calculated with molecular replacement
using PHASER (46). The search model was derived from an
unpublished 1.95 Å resolution structure of PYCR1 (PDB code
2IZZ). Coot (47) and phenix.refine (48) were used for model
building and refinement. The B-factor model consisted of one
TLS group per protein chain and an isotropic B-factor for each
non-hydrogen atom. MolProbity (49) was used for structure
validation. Structure refinement statistics are shown in Table 1.
Analytical ultracentrifugation
Sedimentation-velocity experiments were conducted with a
BeckmanXL-I analytical ultracentrifuge using anAn50Ti rotor
and a two-sector cell. Sample sedimentation was continuously
monitored at 20 °C using Rayleigh interference optics at 35,000
rpm for a total of 300 scans spaced at 2-min intervals. To
observe concentration dependence of oligomerization, sedi-
mentation-velocity experiments were performed at two differ-
ent protein concentrations as determined by the Pierce BCA
protein assay.
Sedimentation-velocity data were processed using Sedfit
(50), assuming a partial specific volume of 0.73ml/g. Analysis of
the data in Sedfit allowed for determination of apparent sedi-
mentation coefficient (c(S)) and molecular mass (c(M)) distri-
butions. The approximate frictional ratio for decameric PYCR1
was determined by allowing the value to vary in the c(S) calcu-
lation of the 6 mg/ml PYCR1 sample. The frictional ratio
refined to a value of 1.94. This value was applied to the analysis
of the 0.8 mg/ml sample for consistency in decamer peak iden-
tification. Analyzed data were normalized and plotted using
Origin 2016.
Kinetic measurements
All PYCR1 kinetic data were collected in triplicate using a
Varian Cary BIO 50 UV-visible spectrophotometer following
procedures adapted from De Ingeniis et al. (8). PYCR enzyme
activity assays were performed by measuring the P5C-depen-
dent oxidation of NADPH (Sigma-Aldrich) or NADH (Sigma-
Aldrich) at 340 nm (340
 6,200 M1 cm1) and 380 nm (1,314
M1 cm1) as described previously (8). DL-P5Cwas synthesized
according to a previous protocol (51) involving periodation of
DL-5-hydroxylysine and stored in 1 M HCl at 4 °C. DL-P5C was
quantified using o-aminobenzaldehyde and neutralized to pH
7.5 with 1 M Tris-HCl (pH 9.0) immediately before assays (51–
53). NADH and NADPH stock concentrations were quantified
at 340 nm. Assays (600-l total volume) were performed at
37 °C in 0.1 MTris-HCl (pH 7.5), 0.01% Brij-35 detergent (Santa
Cruz Biotechnology), 1 mM EDTA disodium salt (Fisher), using
0.006 and 0.06 M PYCR1 wild-type and mutant T238A
enzymes. The Km and kcat for NADH and NADPH were deter-
mined by varying NADH (0–650 M) and NADPH (0–2000
M) while holding the DL-P5C concentration fixed at 3.5 mM.
The kinetic parameters for P5C were determined by varying
DL-P5C (0–3.5 mM) and holding NADPH fixed at 500 M. The
ionic strength in assays in which DL-P5C varied was kept con-
stant at 450 mM, using 1 M TrisCl (pH 7.5) as a balancing
buffer (52). Reaction traces were followed for 2.5 min, and data
were fit to theMichaelis-Menten equation with SigmaPlot ver-
sion 12.0 to determine the kinetic parameters (31, 54). For esti-
mating the Km for L-P5C, the concentration of L-P5C was con-
sidered to be half the total DL-P5C concentration.
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